Bactiguard Holding AB (publ) (BACTI-B) - Cash Flow Conversion Efficiency

Latest as of December 2025: 0.037x

Based on the latest financial reports, Bactiguard Holding AB (publ) (BACTI-B) has a cash flow conversion efficiency ratio of 0.037x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr11.69 Million ≈ $1.26 Million USD) by net assets (Skr314.93 Million ≈ $33.89 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Bactiguard Holding AB (publ) - Cash Flow Conversion Efficiency Trend (2009–2025)

This chart illustrates how Bactiguard Holding AB (publ)'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Read debt load of Bactiguard Holding AB (publ) for a breakdown of total debt and financial obligations.

Bactiguard Holding AB (publ) Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Bactiguard Holding AB (publ) ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Global Fashion Group SA
XETRA:GFG
-0.160x
Premium Snacks Nordic AB
ST:SNX
0.028x
Permianville Royalty Trust
NYSE:PVL
0.058x
MacroWell OMG Digital Entertainment Co Ltd
TWO:3687
0.007x
Seafco Public Company Limited
BK:SEAFCO
0.073x
Outset Medical Inc
NASDAQ:OM
-0.050x
Careium AB
ST:CARE
0.102x
Thorney Opportunities Ltd
AU:TOP
-0.036x

Annual Cash Flow Conversion Efficiency for Bactiguard Holding AB (publ) (2009–2025)

The table below shows the annual cash flow conversion efficiency of Bactiguard Holding AB (publ) from 2009 to 2025. For the full company profile with market capitalisation and key ratios, see Bactiguard Holding AB (publ) market capitalisation.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 Skr314.93 Million
≈ $33.89 Million
Skr-1.49 Million
≈ $-160.02K
-0.005x -106.20%
2024-12-31 Skr328.34 Million
≈ $35.33 Million
Skr24.99 Million
≈ $2.69 Million
0.076x +151.36%
2023-12-31 Skr353.18 Million
≈ $38.01 Million
Skr-52.33 Million
≈ $-5.63 Million
-0.148x -2498.76%
2022-12-31 Skr495.71 Million
≈ $53.35 Million
Skr3.06 Million
≈ $329.52K
0.006x -53.91%
2021-12-31 Skr541.45 Million
≈ $58.27 Million
Skr7.26 Million
≈ $780.86K
0.013x +612.72%
2020-12-31 Skr373.35 Million
≈ $40.18 Million
Skr702.00K
≈ $75.55K
0.002x -98.65%
2019-12-31 Skr386.69 Million
≈ $41.61 Million
Skr53.98 Million
≈ $5.81 Million
0.140x +410.15%
2018-12-31 Skr370.82 Million
≈ $39.91 Million
Skr-16.69 Million
≈ $-1.80 Million
-0.045x -384.84%
2017-12-31 Skr387.11 Million
≈ $41.66 Million
Skr6.12 Million
≈ $658.29K
0.016x +149.70%
2016-12-31 Skr390.33 Million
≈ $42.01 Million
Skr-12.41 Million
≈ $-1.34 Million
-0.032x +36.16%
2015-12-31 Skr417.44 Million
≈ $44.92 Million
Skr-20.79 Million
≈ $-2.24 Million
-0.050x +27.72%
2014-12-31 Skr518.71 Million
≈ $55.82 Million
Skr-35.74 Million
≈ $-3.85 Million
-0.069x +78.45%
2013-12-31 Skr140.95 Million
≈ $15.17 Million
Skr-45.07 Million
≈ $-4.85 Million
-0.320x -13.00%
2012-12-31 Skr144.60 Million
≈ $15.56 Million
Skr-40.92 Million
≈ $-4.40 Million
-0.283x -1883.43%
2011-12-31 Skr187.86 Million
≈ $20.22 Million
Skr-2.68 Million
≈ $-288.41K
-0.014x -107.36%
2010-12-31 Skr292.61 Million
≈ $31.49 Million
Skr56.71 Million
≈ $6.10 Million
0.194x -22.88%
2009-12-31 Skr317.39 Million
≈ $34.16 Million
Skr79.76 Million
≈ $8.58 Million
0.251x --

About Bactiguard Holding AB (publ)

ST:BACTI-B Sweden Medical Devices
Market Cap
$61.64 Million
Skr572.76 Million SEK
Market Cap Rank
#21069 Global
#379 in Sweden
Share Price
Skr18.45
Change (1 day)
+2.50%
52-Week Range
Skr14.75 - Skr37.90
All Time High
Skr205.00
About

Bactiguard Holding AB (publ), a medTech company, provides infection prevention technology and solutions in orthopedics, cardiology, neurology, urology, and vascular access areas. It also operates through license partnerships with global MedTech companies that apply the technology to medical devices and sell them under own brand and co-branded. The company also has a portfolio of wound management … Read more